Intervacc AB (publ) today announces that Strangvac®, the company’s innovative vaccine against strangles in horses, has been approved for import into New Zealand under a Special Circumstances Permit. The ... Read more
Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards the ... Read more
Intervacc AB (publ), a growth company within veterinary medicine with its vaccine Strangvac® registered in 16 European countries, today announces that Chairman of the Board Håkan Björklund has handed over to ... Read more
Intervacc AB (publ) held its Annual General Meeting (”AGM”) on Wednesday 13 May 2026, at which the following resolutions were made.
